Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
Advertisement
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcast
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Lilly Lecture 1989

Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach

  1. Richard N Bergman
  1. Division of Metabolism, Department of Physiology and Biophysics, University of Southern California Medical School Los Angeles, California
  1. Address correspondence and reprint requests to Richard N. Bergman, PhD, Department of Physiology and Biophysics, University of Southern California Medical School, 2025 Zonal Avenue, Los Angeles, CA 90033.
Diabetes 1989 Dec; 38(12): 1512-1527. https://doi.org/10.2337/diab.38.12.1512
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Glucose tolerance depends on a complex interaction among insulin secretion from the β-cells, clearance of the hormone, and the actions of insulin to accelerate glucose disappearance and inhibit endogenous glucose production. An additional factor, less well recognized, is the ability of glucose per se, independent of changes in insulin, to increase glucose uptake and suppress endogenous output (glucose effectiveness). These factors can be measured in the intact organism with physiologically based minimal models of glucose utilization and insulin kinetics. With the glucose minimal model, insulin sensitivity (SI) and glucose effectiveness (SG) are measured by computer analysis of the frequently sampled intravenous glucose tolerance test. The test involves intravenous injection of glucose followed by tolbutamide or insulin and frequent blood sampling. SI varied from a high of 7.6 × 10−4 min−1 · μU−1 · ml−1 in young Whites to 2.3 × 10−4 min−1 · μU−1 · ml−1 in obese nondiabetic subjects; in all of the nondiabetic subjects, SG was normal. In subjects with non-insulin-dependent diabetes mellitus (NIDDM), not only was SI reduced 90% below normal (0.61 ± 0.16 × 10−4 min−1 · μU−1 · ml−1), but in this group alone, SG was reduced (from 0.026 ± 0.008 to 0.014 ± 0.002 min−1); thus, defects in SI and SG are synergistic in causing glucose intolerance in NIDDM. One assumption of the minimal model is that the time delay in insulin action on glucose utilization in vivo is due to sluggish insulin transport across the capillary endothelium. This was tested by comparing insulin concentrations in plasma with those in lymph (representing interstitial fluid) during euglycemic-hyperinsulinemic glucose clamps. Lymph insulin was lower than plasma insulin at basal (12 vs. 18 μU/ml) and at steady state, indicating significant loss of insulin from the interstitial space, presumably due to cellular uptake of the insulin-receptor complex. Additionally, during clamps, lymph insulin changed more slowly than plasma insulin, but the rate of glucose utilization followed a time course identical with that of lymph (r = .96) rather than plasma (r = .71). Thus, lymph insulin, which may be reflective of interstitial fluid, is the signal to which insulin-sensitive tissues are responding. These studies support the concept that, at physiological insulin levels, the time for insulin to cross the capillary endothelium is the process that determines the rate of insulin action in vivo. In separate experiments, a similar intimate relationship was found between lymph insulin and glucose utilization estimated from the minimal model, supporting the accuracy of the minimal model as a mathematical representation of insulin action in vivo. Additional factors in glucose tolerance are insulin secretion and clearance. We proposed a model of insulin/C-peptide kinetics, derived from the original conception of Eaton and Polonsky, in which determination of C-peptide kinetics in each individual is unnecessary if insulin and C-peptide kinetics are modeled simultaneously. Prehepatic insulin secretion after glucose injection was calculated in healthy women; total insulin secretion was 22.2 nmol; first-phase insulin averaged 38% of total, but there was wide variation among healthy subjects. The ability to determine insulin secretion, insulin action, and glucose effectiveness from modeling allowed us to investigate their interaction. We propose that in healthy individuals, there is a balance between secretion and insulin action such that insulin secretion × insulin sensitivity = constant. Thus, with insulin resistance, it is proposed that a normal β-cell will increase its sensitivity to glucose appropriately, staving off impaired glucose tolerance. This concept is supported by data in healthy pregnant women, in whom the reciprocal relationship is shown to exist and impaired glucose tolerance is not observed despite substantial insulin resistance (S, reduced to 1.8 × 10−4 min−1 · μU−1 · ml−1). In subjects at risk for diabetes, e.g., HLA-identical siblings of insulin-dependent diabetic subjects and Pima Indians, insulin sensitivity × secretion < normal constant value. Additionally, Pima Indians with the lowest sensitivity/secretion product appear to be at highest risk for developing NIDDM. Finally, with simulation of the models, we examined the relative importance of individual and compound defects of SI, SG, and insulin secretion to glucose intolerance. Although no individual defect (≤80%) of these factors causes diabetic glucose tolerance (KG < 1), compound defects are remarkably synergistic, with a combined SI/SG defect being the most severe (KG = 0.60), and an SG defect being a requisite component for diabetic glucose tolerance.

  • Received August 11, 1989.
  • Revision received August 16, 1989.
  • Accepted August 16, 1989.
  • Copyright © 1989 by the American Diabetes Association
PreviousNext
Back to top
Advertisement

In this Issue

December 1989, 38(12)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Richard N Bergman
Diabetes Dec 1989, 38 (12) 1512-1527; DOI: 10.2337/diab.38.12.1512

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Richard N Bergman
Diabetes Dec 1989, 38 (12) 1512-1527; DOI: 10.2337/diab.38.12.1512
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org
Advertisement

© 2019 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.